Dupilumab, a recombinant monoclonal antibody specific for the type-I (IL-4Rα/γC) and type-II receptor (IL-4Rα/IL-13Rα), was recently approved for the treatment of AD, nasal polyposis, and asthma. Here, IL4R is linked to Alzheimer disease.